Magdalena Krzystolik, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macular Degeneration | 7 | 2020 | 981 | 1.130 |
Why?
|
| Angiogenesis Inhibitors | 9 | 2020 | 2038 | 1.040 |
Why?
|
| Blast Injuries | 1 | 2024 | 302 | 0.740 |
Why?
|
| Vascular Endothelial Growth Factor A | 8 | 2020 | 3506 | 0.710 |
Why?
|
| Eye Injuries | 2 | 2021 | 245 | 0.700 |
Why?
|
| Vision, Low | 1 | 2020 | 168 | 0.640 |
Why?
|
| Intravitreal Injections | 6 | 2020 | 345 | 0.620 |
Why?
|
| Retinal Vein Occlusion | 2 | 2016 | 137 | 0.620 |
Why?
|
| Coronavirus | 1 | 2020 | 158 | 0.600 |
Why?
|
| Aptamers, Nucleotide | 4 | 2019 | 166 | 0.580 |
Why?
|
| Economics, Pharmaceutical | 1 | 2016 | 87 | 0.540 |
Why?
|
| Military Personnel | 1 | 2024 | 1133 | 0.510 |
Why?
|
| Athletic Injuries | 1 | 2021 | 1154 | 0.400 |
Why?
|
| Choroidal Neovascularization | 5 | 2019 | 343 | 0.340 |
Why?
|
| Visual Acuity | 7 | 2020 | 2530 | 0.280 |
Why?
|
| Iris | 1 | 2006 | 239 | 0.250 |
Why?
|
| Diabetic Retinopathy | 3 | 2015 | 1210 | 0.250 |
Why?
|
| Macular Edema | 3 | 2015 | 359 | 0.250 |
Why?
|
| Guideline Adherence | 1 | 2013 | 2266 | 0.210 |
Why?
|
| Immunoglobulin Fragments | 1 | 2002 | 84 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3132 | 0.210 |
Why?
|
| Hyphema | 1 | 2021 | 26 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3239 | 0.200 |
Why?
|
| Play and Playthings | 1 | 2021 | 79 | 0.200 |
Why?
|
| Aspirin | 1 | 2013 | 3282 | 0.190 |
Why?
|
| Tropism | 1 | 2020 | 41 | 0.190 |
Why?
|
| Phacoemulsification | 2 | 2006 | 149 | 0.190 |
Why?
|
| Silicone Oils | 1 | 2000 | 22 | 0.180 |
Why?
|
| Pandemics | 1 | 2020 | 8387 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 4 | 2019 | 9275 | 0.170 |
Why?
|
| Porphyrins | 2 | 2014 | 348 | 0.170 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 694 | 0.170 |
Why?
|
| Gases | 1 | 2000 | 197 | 0.170 |
Why?
|
| Lymphokines | 1 | 2002 | 949 | 0.160 |
Why?
|
| Endophthalmitis | 2 | 2020 | 262 | 0.160 |
Why?
|
| Environment | 1 | 2024 | 1124 | 0.150 |
Why?
|
| Aspergillus niger | 1 | 1997 | 17 | 0.150 |
Why?
|
| Retinal Detachment | 2 | 2006 | 411 | 0.150 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2020 | 664 | 0.140 |
Why?
|
| Uveal Diseases | 1 | 1996 | 45 | 0.140 |
Why?
|
| Retinal Perforations | 1 | 1998 | 131 | 0.140 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 2636 | 0.130 |
Why?
|
| Eye Infections, Fungal | 1 | 1997 | 110 | 0.130 |
Why?
|
| Angiomatosis | 1 | 2015 | 49 | 0.130 |
Why?
|
| Anterior Eye Segment | 1 | 1996 | 152 | 0.130 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 1995 | 65 | 0.130 |
Why?
|
| Trabeculectomy | 1 | 1997 | 162 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2020 | 3772 | 0.130 |
Why?
|
| Aspergillosis | 1 | 1997 | 235 | 0.130 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2015 | 51 | 0.130 |
Why?
|
| Off-Label Use | 1 | 2016 | 169 | 0.120 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 1996 | 189 | 0.120 |
Why?
|
| Eyelid Neoplasms | 1 | 1995 | 94 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2020 | 9960 | 0.110 |
Why?
|
| Orbital Neoplasms | 1 | 1995 | 225 | 0.110 |
Why?
|
| Retinal Neovascularization | 1 | 2015 | 244 | 0.110 |
Why?
|
| Nurse's Role | 1 | 2015 | 209 | 0.110 |
Why?
|
| Wet Macular Degeneration | 1 | 2015 | 146 | 0.110 |
Why?
|
| Sarcoidosis | 1 | 1998 | 505 | 0.110 |
Why?
|
| Eye Diseases | 1 | 1998 | 668 | 0.100 |
Why?
|
| Macula Lutea | 2 | 2007 | 151 | 0.100 |
Why?
|
| Arteriovenous Fistula | 1 | 2015 | 315 | 0.100 |
Why?
|
| Drug Compounding | 1 | 2012 | 243 | 0.100 |
Why?
|
| Drug Contamination | 1 | 2012 | 148 | 0.100 |
Why?
|
| Injections | 2 | 2006 | 840 | 0.100 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 2420 | 0.100 |
Why?
|
| Vitrectomy | 2 | 2006 | 365 | 0.090 |
Why?
|
| Ophthalmology | 1 | 2016 | 508 | 0.090 |
Why?
|
| Humans | 22 | 2024 | 744220 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2020 | 8321 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1996 | 2234 | 0.070 |
Why?
|
| Fluorescein Angiography | 3 | 2015 | 940 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 15161 | 0.070 |
Why?
|
| Skin Diseases | 1 | 2015 | 1065 | 0.070 |
Why?
|
| Glaucoma, Neovascular | 1 | 2006 | 36 | 0.070 |
Why?
|
| Gonioscopy | 1 | 2006 | 157 | 0.070 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2006 | 116 | 0.060 |
Why?
|
| Choroid | 1 | 2006 | 322 | 0.060 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2006 | 192 | 0.060 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 1071 | 0.060 |
Why?
|
| Laser Coagulation | 2 | 2006 | 326 | 0.060 |
Why?
|
| Adolescent | 3 | 2021 | 85759 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 3395 | 0.050 |
Why?
|
| Uveitis, Anterior | 1 | 2002 | 101 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 772 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2021 | 40992 | 0.050 |
Why?
|
| Rod Opsins | 1 | 2000 | 111 | 0.050 |
Why?
|
| Vitreous Body | 1 | 2002 | 389 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2021 | 77426 | 0.050 |
Why?
|
| Macaca fascicularis | 1 | 2002 | 910 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 2 | 2015 | 2657 | 0.040 |
Why?
|
| Retina | 2 | 2020 | 2616 | 0.040 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 2000 | 177 | 0.040 |
Why?
|
| Aged | 8 | 2020 | 163253 | 0.040 |
Why?
|
| Middle Aged | 9 | 2019 | 213367 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 7281 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 3474 | 0.040 |
Why?
|
| Male | 8 | 2021 | 350027 | 0.040 |
Why?
|
| Dacryocystitis | 1 | 1998 | 70 | 0.040 |
Why?
|
| Lens Capsule, Crystalline | 1 | 1997 | 43 | 0.040 |
Why?
|
| Safety | 1 | 2002 | 1185 | 0.040 |
Why?
|
| Itraconazole | 1 | 1997 | 43 | 0.040 |
Why?
|
| United States | 2 | 2016 | 69867 | 0.040 |
Why?
|
| Fundus Oculi | 1 | 1998 | 473 | 0.040 |
Why?
|
| Amphotericin B | 1 | 1997 | 137 | 0.040 |
Why?
|
| Pneumocystis | 1 | 1996 | 57 | 0.040 |
Why?
|
| Prevalence | 1 | 2013 | 15226 | 0.030 |
Why?
|
| Exudates and Transudates | 1 | 1996 | 171 | 0.030 |
Why?
|
| Ophthalmic Solutions | 1 | 1997 | 317 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 56436 | 0.030 |
Why?
|
| Incidence | 1 | 2013 | 20945 | 0.030 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1996 | 249 | 0.030 |
Why?
|
| Child | 2 | 2021 | 77679 | 0.030 |
Why?
|
| Uveitis | 1 | 1998 | 375 | 0.030 |
Why?
|
| Adult | 5 | 2021 | 214035 | 0.030 |
Why?
|
| Conjunctiva | 1 | 1998 | 494 | 0.030 |
Why?
|
| Sputum | 1 | 1996 | 476 | 0.030 |
Why?
|
| Female | 6 | 2021 | 380197 | 0.030 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 1993 | 136 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 1997 | 730 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 4929 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2015 | 63119 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 1998 | 1265 | 0.020 |
Why?
|
| Microscopy | 1 | 1996 | 903 | 0.020 |
Why?
|
| Glaucoma, Open-Angle | 1 | 1997 | 711 | 0.020 |
Why?
|
| Cartilage | 1 | 1993 | 818 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 1998 | 2108 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 1998 | 6485 | 0.020 |
Why?
|
| Biopsy | 1 | 1998 | 6757 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 1995 | 4841 | 0.020 |
Why?
|
| Rupture | 1 | 2006 | 433 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 1998 | 4151 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2006 | 15294 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1998 | 20123 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1996 | 5982 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 18027 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1998 | 12961 | 0.010 |
Why?
|
| Disease Progression | 1 | 1998 | 13280 | 0.010 |
Why?
|
| Observer Variation | 1 | 2007 | 2593 | 0.010 |
Why?
|
| Photochemotherapy | 1 | 2006 | 807 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 57768 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 1998 | 35423 | 0.010 |
Why?
|
| Retinal Rod Photoreceptor Cells | 1 | 2000 | 195 | 0.010 |
Why?
|
| Quality of Life | 1 | 2020 | 12805 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 1950 | 0.010 |
Why?
|
| Cell Count | 1 | 2000 | 1854 | 0.010 |
Why?
|
| Species Specificity | 1 | 2000 | 2480 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2000 | 1731 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2000 | 2007 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2000 | 1971 | 0.010 |
Why?
|
| Animals | 3 | 2002 | 168788 | 0.010 |
Why?
|
| Notochord | 1 | 1993 | 36 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2007 | 3336 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2000 | 13036 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2000 | 6386 | 0.010 |
Why?
|
| Chick Embryo | 1 | 1993 | 982 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1993 | 841 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 19907 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1993 | 2335 | 0.010 |
Why?
|
| Extremities | 1 | 1993 | 865 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 18116 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 11368 | 0.000 |
Why?
|
| Prognosis | 1 | 2006 | 29050 | 0.000 |
Why?
|
| Collagen | 1 | 1993 | 2689 | 0.000 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 11732 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2007 | 53280 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2000 | 21824 | 0.000 |
Why?
|
| Gene Expression | 1 | 1993 | 7799 | 0.000 |
Why?
|
| Risk Factors | 1 | 2006 | 72280 | 0.000 |
Why?
|
| Mice | 1 | 2000 | 81178 | 0.000 |
Why?
|
| Brain | 1 | 1993 | 26413 | 0.000 |
Why?
|